Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027919 · ClinicalTrials.gov registry record · Phase 2
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
A Phase 2 study of Opioid Use Disorder and Opioid Withdrawal, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05027919: Recruiting Phase 2 study of Opioid Use Disorder and Opioid Withdrawal, sponsored by University of Maryland, Baltimore.
NCT05027919 is a Phase 2 study of Opioid Use Disorder and Opioid Withdrawal that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 60 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05027919, a Phase 2 study of Opioid Use Disorder and Opioid Withdrawal, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.
Primary Outcome
Withdrawal severity as assessed by the Subjective Opioid Withdrawal Scale. (The score range is 0 through 64) with higher score indicating more severe withdrawal.
Conditions Studied
Interventions
- DRUG Hydromorphone
- DRUG Lofexidine
- DRUG Naloxone + lofexidine pretreatment
- DRUG Naloxone + placebo pretreatment
Study Locations (1)
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
What NCT05027919 shows while recruiting
NCT05027919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Hydromorphone is the first listed.
NCT05027919 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05027919 about?
NCT05027919 is a clinical study titled "Assessing a Clinically-meaningful Opioid Withdrawal Phenotype". Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.
What is the current status of trial NCT05027919?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-12-01. Estimated completion is 2027-02-28.
What conditions does trial NCT05027919 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Withdrawal, Opioid Craving.
What interventions are being tested in trial NCT05027919?
The interventions under investigation include: Hydromorphone (DRUG), Lofexidine (DRUG), Naloxone + lofexidine pretreatment (DRUG), Naloxone + placebo pretreatment (DRUG).
Who is sponsoring clinical trial NCT05027919?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027919 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05027919's enrollment target sits among peer trials
60 156th of 257 higher than 91 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI